SKB518
Phase 2Small molecule
SKB518 is one of 114 small molecule programs targeting Combination Therapy. It is currently in Phase 2.
3
Indications
3
Total Trials
3
Active Trials
113
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
249 competitors in Patients With Advanced Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Gemzar
Johnson & JohnsonPhase 2
Eloxatin
TevaPhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Paraplatin
AAvyxa
Phase 2
Camptosar
PfizerPhase 2
Tecentriq
RochePhase 2
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 2
Imfinzi
AstraZenecaPhase 2
Perjeta
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Combination Therapy1 trial
A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors
Not yet recruiting·SSichuan Kelun Pharmaceutical Research Institute Co., Ltd.·Phase 2·NCT07448922·290 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SKB518. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details